Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of inhaled SNG001 in mechanically ventilated patients with respiratory virus infection
NL-OMON60340Phase 2Completed
- Sponsor
- Synairgen
- Start
- Nov 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of interferon beta-1a in Viral lower respiratory tract infection (VLRTI) (3 arms), sponsored by Synairgen. Primary endpoints: Occurrence and severity of adverse events and serious adverse events and All-cause mortality within 28 days from randomisation. Started Nov 2025; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
Viral lower respiratory tract infection (VLRTI)
Beyond the preview
Go deeper on NL-OMON60340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60340.